Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. - Wikidata - awgldk - TriplyDB

Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients.

Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients.

http://www.wikidata.org/entity/Q40082103

about

Overexpression of cathepsin F, matrix metalloproteinases 11 and 12 in cervical cancer Circulating biomarkers to monitor cancer progression and treatment Progression of cutaneous melanoma: implications for treatment Epigenetic regulation in human melanoma: past and future Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications The Ras-association domain family (RASSF) members and their role in human tumourigenesis.Methylation screening of the TGFBI promoter in human lung and prostate cancer by methylation-specific PCR.Oncogenic BRAFV600E induces expression of neuronal differentiation marker MAP2 in melanoma cells by promoter demethylation and down-regulation of transcription repressor HES1.The regulation of miRNA-211 expression and its role in melanoma cell invasiveness.Constitutional promoter methylation and risk of familial melanoma Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy.Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients Estrogen receptor-alpha methylation predicts melanoma progression Detection of erbB2 copy number variations in plasma of patients with esophageal carcinoma.Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies Association of TNFRSF10D DNA-methylation with the survival of melanoma patients.Identification of driver and passenger DNA methylation in cancer by epigenomic analysis.Development of sporadic microsatellite instability in colorectal tumors involves hypermethylation at methylated-in-tumor loci in adenoma Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations Functional modulation of IGF-binding protein-3 expression in melanoma Aberrant DNA methylation in malignant melanoma Aberrant DNA hypermethylation patterns lead to transcriptional silencing of tumor suppressor genes in UVB-exposed skin and UVB-induced skin tumors of mice.DNA-methylation profiling distinguishes malignant melanomas from benign nevi.RASSF1A suppresses melanoma development by modulating apoptosis and cell-cycle progression.The Levels of H11/HspB8 DNA methylation in human melanoma tissues and xenografts are a critical molecular marker for 5-Aza-2'-deoxycytidine therapy.Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins.O6-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies.AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome Aberrant hypermethylation in primary tumours and sentinel lymph node metastases in paediatric patients with cutaneous melanoma.Epigenetic biomarkers in skin cancer.The relationship between RASSF1A gene promoter methylation and the susceptibility and prognosis of melanoma: A meta-analysis and bioinformatics Tumor-Related Methylated Cell-Free DNA and Circulating Tumor Cells in Melanoma.Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma.Epigenetic events in malignant melanoma.The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia.Prognostic molecular biomarkers for cutaneous malignant melanoma Augmentation of effects of interferon-stimulated genes by reversal of epigenetic silencing: potential application to melanoma.Biomarker and animal models for assessment of retinoid efficacy in cancer chemoprevention.

P2860

Q21261212-55A76B55-B8EF-466B-A24B-74DAAB46F7EB Q26745985-596CD297-66AA-4BDB-A07F-8456DADA2A4C Q27001734-01483BE6-3D1C-48ED-AA3C-48FE0977E982 Q28085681-94C07655-10FA-4D1F-BE19-A72F6D0C7B84 Q28087759-2C9FD692-F929-4334-AEFF-7B74CAC9980D Q28474843-D3BBB185-68AC-4D04-9424-8F8E84C19E7F Q31121564-FC8C3290-A20E-454C-968A-BB9D4C525AC5 Q33373839-AC4B5705-C174-4717-9184-F64C126C3BE9 Q33581231-B249DB33-67C3-4A36-BA4D-FBC6136A62B6 Q33745034-0DD430A6-5DAE-4EB4-B1E4-34B026DE82F2 Q33779164-474604C3-4202-4AA6-A262-8ADACC541ADC Q33796956-FCD4E616-1C13-4937-9E7D-AFF82609A3E8 Q33797039-6A2E4222-1A44-4B77-8DA4-8782E1E29FE3 Q33797076-628AF2E9-3899-4FF8-A011-469DAE55D176 Q33868284-36F59726-F2F1-4699-A500-A0B47DFECD91 Q33980682-C9CBA2C7-81E9-4C57-A5A6-68EED47D4408 Q34072329-2F14BC7C-47E3-491C-824C-D248C438E9C8 Q34181789-EFE09551-6A40-494D-9B07-8603D093469F Q34254446-2D2D5602-B107-4884-A4D5-E77D1A2318F6 Q34299814-4B213F59-5E8D-40D2-8CEF-02BB5B7B3AE5 Q34359695-23870846-CC77-4886-B58F-E9D8337467DB Q34505279-6B707DC9-A4E7-4702-A5FE-6226BA0B9949 Q34516587-C591D861-1CF1-49F0-974F-040F96FBC872 Q34734084-CA7EB2F8-CB2C-4D77-890C-2E17F10F3AB8 Q34775571-5DADCF57-5A34-48EE-8E42-D281F57F6696 Q34843148-C390D52D-4F7B-44AD-A895-6D1300DE78DF Q35037004-1E76BDFF-9B73-479E-BC24-84F412A6AF68 Q35769170-AFA44F10-28A0-417B-9475-11C0149D5871 Q35844142-F612016E-5A50-43D4-B202-33FD2D0B5D05 Q35962455-358C72F8-8F50-4E3B-8301-BE3276F83D54 Q35989635-8F3D3376-20AA-4F41-9BB6-7F417168ADFE Q36080974-5881B884-71EB-42B2-9535-161D21DED6C3 Q36282768-48603BB4-5A54-4F40-BEDA-1D06738190CD Q36443927-4078BB19-7C11-457B-91C0-F19B2E11597B Q36452245-94AA69A9-3745-45F6-BAC5-DB92D6517BA2 Q36764224-8ACBE386-A84F-4B34-BCDF-C6FA5E52EC21 Q36798179-04033BD4-2463-4077-9E6A-FFA4EDA4FC11 Q36905877-D0519DC9-18C3-4FA6-A124-08FC66472BBF Q36906147-8F889401-9900-4315-93F8-069BFAF9CF16 Q36920773-316D3A30-5E17-4CEB-8248-18CE8DC9C029

P2860

Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients.

http://www.wikidata.org/entity/Q40082103

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Profiling epigenetic inactivat ...... m cutaneous melanoma patients.

@en

type

label

Profiling epigenetic inactivat ...... m cutaneous melanoma patients.

@en

prefLabel

Profiling epigenetic inactivat ...... m cutaneous melanoma patients.

@en

P1433

Q40082103-9D2EB41F-376C-4EE8-9417-37B6D814B272

P1476

Q40082103-CE96A838-543E-4217-9F85-15D4341D0F64

P2093

Q40082103-482B28E6-F90F-41BB-A1C0-22CC36C71026

Q40082103-4F0ABDC3-16B9-439F-9A46-6DE87F3FBA45

Q40082103-61CBBD69-4BDC-4F2D-B27B-CED365642B9E

Q40082103-AB605A58-48A3-4FAD-811D-D6615E7DFB7A

Q40082103-C4C43A35-92C5-492B-BB47-C984A305BA94

Q40082103-CF6202C3-0F1A-4C63-8FBA-B33664005AEE

P2860

Q40082103-1874B56B-0F95-4E27-952A-3AE956D626B0

Q40082103-1FE386B7-EF01-4730-BC7C-92845B776954

Q40082103-29FDFEDA-236F-4ACD-A178-280813525537

Q40082103-2ACA7F7E-67DE-4DC8-8523-B10ED4E258AB

Q40082103-2F2D53ED-9540-4415-81E4-76D9F41236A0

Q40082103-2F5D3CDF-DAC4-440A-B0AA-67431030766A

Q40082103-32E0E5EF-291E-4A06-B59F-DC0E9EBE66D3

Q40082103-36DE116C-FE6D-44E7-81A2-B3723694E504

Q40082103-4FDD1F55-F363-4A2F-9709-1BEDDF3403A9

Q40082103-518366DF-D1F3-41D2-BB21-EB612B299968

P2888

Q40082103-47525020-343C-491B-85DB-B5344AF6E6AC

P304

Q40082103-B466502C-667D-48BB-A147-8E01919704E9

P31

Q40082103-383E6999-4443-4625-9817-F803EA62F466

P356

Q40082103-A501D685-E9A3-424B-A0A7-665AFECC4ED7

P407

Q40082103-D08104FE-0EEE-4FD5-917D-F8F6EFDA3203

P433

Q40082103-B2098137-B85F-495F-9BF1-3D21B6AE33FB

P478

Q40082103-B72887C6-E2C1-4730-8805-780999F51716

P50

Q40082103-35AC5639-5109-4700-ACB6-95C8D88295B6

P577

Q40082103-E1321502-5349-4ECD-AFAB-EBC21EF6C7E1

P5875

Q40082103-6D66D64D-C495-4019-81A6-E3DF51CCFED8

P6179

Q40082103-52360B9C-C676-4979-91AD-0482E9F8B1EC

P698

Q40082103-A02ADB91-CFF6-4B1D-9771-E2B1596AE150

P932

Q40082103-4F61B73D-687A-4CC8-B995-1A5AC71E6D5C

P356

P1433

P1476

Profiling epigenetic inactivat ...... m cutaneous melanoma patients.

@en

P2093

Bret Taback

http://www.w3.org/2001/XMLSchema#string

Christine Kuo

http://www.w3.org/2001/XMLSchema#string

Dave S B Hoon

http://www.w3.org/2001/XMLSchema#string

Donald L Morton

http://www.w3.org/2001/XMLSchema#string

Mia Spugnardi

http://www.w3.org/2001/XMLSchema#string

Sharon K Huang

http://www.w3.org/2001/XMLSchema#string

P2860

The fundamental role of epigenetic events in cancer

Mutations of the BRAF gene in human cancer

A gene hypermethylation profile of human cancer

The RXR heterodimers and orphan receptors

Emerging molecular markers of cancer.

Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3.

Aberrant promoter methylation of multiple genes in non-small cell lung cancers.

DNA hypermethylation in tumorigenesis: epigenetics joins genetics.

Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours.

High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma.

P2888

P304

4014-4022

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.ONC.1207505

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

P577

2004-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8636360

http://www.w3.org/2001/XMLSchema#string

P6179

1049938687

http://www.w3.org/2001/XMLSchema#string

P698

15064737

http://www.w3.org/2001/XMLSchema#string

P932

2856469

http://www.w3.org/2001/XMLSchema#string